Anti-obesity drug with exceptional benefit for preventive cardiology: current results of the SELECT trial
Abstract
In August this year, the main results of the SELECT study, one of the largest surveys in the field of cardiovascular prevention in the obese, were announced. The authors compared subcutaneous administration of 2.4 mg semaglutide once weekly with placebo as "on top" therapy in secondary cardiovascular prevention, with the primary endpoint being 3-point MACE (death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke).
A total of 17,604 non-diabetic patients who were overweight (obese) or obese and had a history of cardiovascular disease were followed for 3-5 years and the expected results are now known - there was a reduction in MACE of more than 20% in the treatment arm compared to the placebo arm, making semaglutide the first anti-obesity drug with a proven benefit on the incidence of cardiovascular events and huge potential in preventive cardiology.